Gene Therapy Using Human FMRP Isoforms Driven by the Human FMR1 Promoter Rescues Fragile X Syndrome Mouse Deficits.

Yiru Jiang,Linkun Han,Jian Meng,Zijie Wang,Yunqiang Zhou,Huilong Yuan,Hui Xu,Xian Zhang,Yingjun Zhao,Jinsheng Lu,Huaxi Xu,Chen Zhang,Yun-wu Zhang

DOI: https://doi.org/10.1016/j.omtm.2022.10.002

IF: 5.849

2022-01-01

Molecular Therapy — Methods & Clinical Development

Abstract:Fragile X syndrome (FXS) is caused by the loss of the fragile X messenger ribonucleoprotein 1 (FMRP) encoded by the FMR1 gene. Gene therapy using adeno-associated virus (AAV) to restore FMRP expression is a promising therapeutic strategy. However, so far AAV gene therapy tests for FXS only utilized rodent FMRPs driven by promoters other than the human FMR1 promoter. Restoration of human FMRP in appropriate cell types and at physiological levels, preferably driven by the human FMR1 promoter, would be more suitable for its clinical use. Herein, we generated two human FMR1 promoter subdomains that effectively drive gene expression. When AAVs expressing two different human FMRP isoforms under the control of a human FMR1 promoter subdomain were administered into bilateral ventricles of neonatal Fmr1 -/y and wild-type (WT) mice, both human FMRP isoforms were expressed throughout the brain in a pattern reminiscent to that of mouse FMRP. Importantly, human FMRP expression attenuated social behavior deficits and stereotyped and repetitive behavior, and reversed dysmorphological dendritic spines in Fmr1 -/y mice, without affecting WT mouse behaviors. Our results demonstrate that human FMR1 promoter can effectively drive human FMRP expression in the brain to attenuate Fmr1 -/y mouse deficits, strengthening the notion of using AAV gene therapy for FXS treatment.